Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page
- Check2 days agoChange DetectedA service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.3%
- Check10 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.3%
- Check17 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.3%
- Check31 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.0%
- Check38 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.0%
- Check45 days agoChange DetectedThe web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with a revision update from v2.16.0 to v2.16.1.SummaryDifference0.4%
Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.